AbbVie Inc. $ABBV Position Boosted by Security National Bank of Sioux City Iowa IA

Security National Bank of Sioux City Iowa IA grew its holdings in AbbVie Inc. (NYSE:ABBV) by 13.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,964 shares of the company’s stock after purchasing an additional 1,995 shares during the period. AbbVie comprises 1.8% of Security National Bank of Sioux City Iowa IA’s portfolio, making the stock its 13th largest holding. Security National Bank of Sioux City Iowa IA’s holdings in AbbVie were worth $4,269,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Burk Holdings LLC purchased a new stake in shares of AbbVie during the second quarter worth $30,000. Marquette Asset Management LLC grew its stake in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Abound Financial LLC purchased a new position in AbbVie in the fourth quarter valued at about $32,000. Principia Wealth Advisory LLC increased its position in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Merkkuri Wealth Advisors LLC purchased a new stake in shares of AbbVie during the 1st quarter worth about $34,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced that Phase 3 CERVINO results for investigational etentamig met both primary endpoints—objective response rate and progression-free survival—in relapsed or refractory multiple myeloma. The results could strengthen AbbVie’s oncology pipeline and diversify growth beyond its immunology franchise. AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio
• Positive Sentiment: New real-world studies found that VRAYLAR improved depressive symptoms, functioning and quality of life among patients with major depressive disorder and bipolar I depression. The additional evidence may support broader adoption of the drug and reinforce AbbVie’s growth outlook in psychiatry. AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR
• Positive Sentiment: Allergan Aesthetics reported statistically significant improvements from skincare regimens and DiamondGlow treatments for people taking medical weight-loss medications, offering a potential commercial opportunity in aesthetics. Allergan Aesthetics Presents New Clinical Data
• Neutral Sentiment: AbbVie declared its regular $1.73 quarterly dividend, payable November 16 to shareholders of record October 15. The payout supports income-focused investors, although the dividend was unchanged during 2026 and therefore provides no new increase catalyst. AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
• Negative Sentiment: Analysts caution that AbbVie’s elevated valuation reflects strong expectations for SKYRIZI, while older products are declining. Any slowdown in SKYRIZI growth could pressure future earnings and the stock’s premium multiple. What Happens To AbbVie Stock If SKYRIZI Slows Down?

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Piper Sandler boosted their price target on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. HSBC lifted their target price on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Morgan Stanley restated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a report on Monday, August 3rd. Finally, Wells Fargo & Company lifted their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $276.64.

AbbVie Price Performance

Shares of NYSE ABBV traded down $0.12 during trading hours on Friday, hitting $263.90. 8,162,526 shares of the company’s stock were exchanged, compared to its average volume of 6,587,046. The company’s 50-day moving average price is $255.24 and its 200-day moving average price is $231.94. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The stock has a market capitalization of $466.26 billion, a price-to-earnings ratio of 74.55, a PEG ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the firm posted $2.97 EPS. The company’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.